Tier 4 — mechanistic

Publisher Correction: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

McDermott MM, Martens CR, Domanchuk KJ, Zhang D, Peek CB, Criqui MH, Ferrucci L, Greenland P, Guralnik JM, Ho KJ, Kibbe MR, Kosmac K, Lloyd-Jones D, Peterson CA, Sufit R, Tian L, Wohlgemuth S, Zhao L, Zhu P, Leeuwenburgh C
Nature communications 2024 15; 1; 6890

Bibliography

PubMed
PMID 39134546
PubMed Central
PMC11319328
DOI
10.1038/s41467-024-51289-7
Funding
Correction notice; funding information belongs to the original study.
Competing interests
Correction notice; consult the original study’s disclosures.

Study snapshot

DesignPublished correction or corrigendum
ModelPublication correction
SampleNo new participants
InterventionCorrection to the NICE PAD report PMID 38871717
DurationPublished correction
EndpointsCorrection of the linked original publication

What the study showed, in plain terms

The notice restored the trial-registration sentence accidentally omitted from the original abstract.

Key findings

The notice restored the trial-registration sentence accidentally omitted from the original abstract.

What this study can and cannot tell us

No additional participants or independent treatment result.

Related papers in the corpus

Tier 2
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
McDermott MM et al. · Nature communications · 2024
Tier 4
Corrigendum to: 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
et al. · Aging cell · 2022
Tier 4
Corrigendum to "Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm"
et al. · International journal of toxicology · 2022
Tier 4
Erratum: Author Correction: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2018

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology